Skip to main content
Premium Trial:

Request an Annual Quote

Biocartis, AstraZeneca Partner on European Lung Cancer Biomarker Study

NEW YORK (GenomeWeb) – Biocartis announced today that it has partnered with AstraZeneca on a European study designed to obtain faster lung cancer molecular diagnostics results.

As part of the agreement, the firms will begin a prospective lung cancer study using Biocartis' Idylla EGFR mutation test in European countries including Belgium, France, Germany, and Italy.

Biocartis highlighted that the study will demonstrate how Idylla, a fully automated real-time PCR-based testing platform, can overcome the complexity and long turnaround time of molecular testing for lung cancer patients by delivering faster and accurate biomarker results.

Financial details regarding the agreement and addition information about the prospective clinical study were not disclosed.

"With this prospective study, we expect once again to demonstrate the positive impact of delivering highly accurate biomarker results in a fast and easy way," Biocartis CEO Herman Verrelst said in a statement.

Biocartis said earlier this month that it is adjusting its guidance for 2018, increasing its projection for new instrument placements and narrowing expectations for cartridge volume. The firm also presented lung adenocarcinoma data on the EGFR assay last month during a presentation at the Association for Molecular Pathology annual meeting.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.